- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00248326
The Genetic Basis of Atrial Fibrillation (AF)
The Genetic Basis of Atrial Fibrillation
The investigators' goal with this research is to:
- Establish a clinical database and a DNA bank for 1000 individuals with AF and 1000 individuals without AF.
- Directly test the hypothesis that known functional polymorphisms in the coding sequences and the promoter regions of cardiac genes (ion channels and genes known to affect survival in the setting of left ventricular dysfunction) predispose individuals to AF.
Over the past decade, advancing techniques and technologies for gene characterization have yielded significant clues as to the molecular mechanism of certain human heart rhythm disorders. The role of ion channel polymorphisms in subjects with AF is unknown. Similarly, it is also not known whether polymorphisms in other genes have an impact on the risk of AF.
The ability to characterize genomic "at-risk" profiles would have many potential benefits for patient care. Paramount among these is:
- Increased oversight or intervention of at-risk subjects, which might prevent unnecessary morbidity and mortality due to AF.
- Further insight into the pathogenesis of AF, which may lead to preventative or curative therapies.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Atrial fibrillation (AF), a heart rhythm disorder, is a major health problem. As many as 3 million US persons are afflicted; this number is expected to rise significantly in coming decades because AF incidence is directly correlated with age. AF is significantly associated with cardiovascular morbidity and mortality.
Our goal with this research is to:
- Establish a clinical database and a DNA bank for 1000 individuals with AF and 1000 individuals without AF.
- Directly test the hypothesis that known functional polymorphisms in the coding sequences and the promoter regions of cardiac genes (ion channels and genes known to affect survival in the setting of left ventricular dysfunction) predispose individuals to AF.
Over the past decade, advancing techniques and technologies for gene characterization have yielded significant clues as to the molecular mechanism of certain human heart rhythm disorders. The role of ion channel polymorphisms in subjects with AF is unknown. Similarly, it is also not known whether polymorphisms in other genes have an impact on the risk of AF.
The ability to characterize genomic "at-risk" profiles would have many potential benefits for patient care. Paramount among these is:
- Increased oversight or intervention of at-risk subjects, which might prevent unnecessary morbidity and mortality due to AF.
- Further insight into the pathogenesis of AF, which may lead to preventative or curative therapies.
Subjects will be recruited from the patient pool of the Cardiovascular Institute (including the Comprehensive Heart Center and the PUH Outpatient Cardiology Clinic). For each subject enrolled, we will record demographic information; etiology and details of heart disease; family history of heart disease; non-cardiac medical history; physical exam findings; medicinal therapy; and results of prior cardiac testing (such as echocardiograms [Echo], gated blood pool scans of heart function [MUGAs], exercise stress tests [ESTs] cardiac catheterizations, and clinical electrophysiology studies [EP Studies]. Records will be maintained with identifiers in a locked file cabinet in the office of the Principal Investigator.
A blood sample of ~10 ml will be drawn from each participating subject on the day of enrollment. Blood samples will be drawn only once from each subject. There is no further follow up required for the subject. Blood will be sent to the University of Pittsburgh School of Medicine Cardiovascular Research Center where nucleated cells will be isolated from whole blood by centrifugation. DNA will be isolated from nucleated cells and stored at the Cardiovascular Research Center (on the 17th floor of the Biomedical Science Tower). All DNA samples will be coded to ensure confidentiality, and maintained in a locked freezer for the duration of the study (5 years). Samples will be destroyed if requested by the subject. Samples (blood and DNA) will be under the control of the Principal Investigator. The DNA samples will be used to identify polymorphisms in ion channel genes, as well as other genes that may be associated with an increased risk of AF. Genotyping of polymorphisms will be performed on the genomic DNA. The genomic DNA will be amplified by polymerase chain reaction method using gene-specific primers. For each polymorphism, genotype will be identified. We will determine the frequency of that genotype in our study population, and attempt to define significant associations with AF.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15213
- University of Pittsburgh Medical Center/Comprehensive Heart Ctr.
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- 18+ years of age
- Able to give informed consent
Exclusion Criteria:
- Inability to provide informed consent
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Case-Control
- Tidsperspektiv: Tvärsnitt
Kohorter och interventioner
Grupp / Kohort |
---|
1
Patients of the Cardiovascular Institute with known cardiac conditions and no history of atrial fibrillation.
|
2
Patients of the Cardiovascular Institute with known cardiac conditions and a history of atrial fibrillation.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: David S. Schwartzman, MD, University of Pittsburgh/UPMC
Publikationer och användbara länkar
Allmänna publikationer
- Gensini F, Padeletti L, Fatini C, Sticchi E, Gensini GF, Michelucci A. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. Pacing Clin Electrophysiol. 2003 Jan;26(1P2):295-8. doi: 10.1046/j.1460-9592.2003.00036.x.
- Lai LP, Lin JL, Lin CS, Yeh HM, Tsay YG, Lee CF, Lee HH, Chang ZF, Hwang JJ, Su MJ, Tseng YZ, Huang SK. Functional genomic study on atrial fibrillation using cDNA microarray and two-dimensional protein electrophoresis techniques and identification of the myosin regulatory light chain isoform reprogramming in atrial fibrillation. J Cardiovasc Electrophysiol. 2004 Feb;15(2):214-23. doi: 10.1046/j.1540-8167.2004.03423.x.
- Gaudino M, Andreotti F, Zamparelli R, Di Castelnuovo A, Nasso G, Burzotta F, Iacoviello L, Donati MB, Schiavello R, Maseri A, Possati G. The -174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication? Circulation. 2003 Sep 9;108 Suppl 1:II195-9. doi: 10.1161/01.cir.0000087441.48566.0d.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 0405107
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Förmaksflimmer
-
Pusan National University HospitalHar inte rekryterat ännuHjärtimplanterbar elektronisk enhet | Atrial High Rate EpisodKorea, Republiken av
-
Atrial Fibrillation NetworkDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Deutsches Zentrum...AvslutadAtrial High Rate EpisoderÖsterrike, Belgien, Bulgarien, Tjeckien, Frankrike, Tyskland, Grekland, Ungern, Italien, Nederländerna, Polen, Portugal, Rumänien, Spanien, Sverige, Ukraina, Storbritannien, Danmark
-
Centre Chirurgical Marie LannelongueRekryteringMedfödd hjärtsjukdom | Sinus Venosus Defekt | Sinus Venosus Atrial Septum DefektFrankrike
-
Assiut UniversityIndragenASD2 (Secundum Atrial Septal Defect)
-
Karolinska InstitutetDanderyd HospitalRekryteringFörmaksflimmer | Förmaksfladder | Supraventrikulärt slag, för tidigt | För tidiga supraventrikulära beats | För tidigt förmakskomplex | Extrasystole, AtrialSverige